Observatory of Patients With Chronic Lymphocytic Leukemia / Lymphocytic Lymphoma or Waldenstrom Disease Infected With COVID-19 (COVID19_LLC-MW)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04391946|
Recruitment Status : Recruiting
First Posted : May 18, 2020
Last Update Posted : August 12, 2020
The COVID-19 epidemic (Coronavirus Disease 2019) which is currently raging in France is an emerging infectious disease linked to a virus of the genus coronavirus (SARS-CoV-2). The first cases were reported in Wuhan, China, in late December 2019 . Globally, it has been placed in the "pandemic" stage by the WHO since March 11, 2020. Coronavirus viruses have been responsible for epidemics in the past such as the SARS epidemic in 2002 (Syndrome Severe Acute Respiratory) linked to the SARS-CoV virus, or the epidemic of MERS (Middle East Respiratory Syndrome) that affected the Middle East in 2012.
Patients with chronic lymphocytic leukemia (CLL) / lymphocytic lymphoma or Waldenstrom Disease (WD) therefore represent a population at high risk of developing a severe form in the event of COVID-19 infection.
To date, no data is available in the literature to assess the impact of the COVID-19 epidemic in this population of patients with CLL / lymphocytic lymphoma or WD.
|Condition or disease||Intervention/treatment|
|Chronic Lymphocytic Leukemia, Lymphocytic Lymphoma or Waldenstrom Disease||Behavioral: Data registry|
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||50 participants|
|Target Follow-Up Duration:||12 Years|
|Official Title:||National Prospective and Retrospective Follow-up of Patients With COVID-19 Infected Chronic Lymphocytic Leukemia / Lymphocytic Lymphoma or Waldenström Disease|
|Actual Study Start Date :||March 14, 2020|
|Estimated Primary Completion Date :||May 1, 2022|
|Estimated Study Completion Date :||December 31, 2022|
- Behavioral: Data registry
Collection of clinical data, treatment regimens and survival data
- Prognostic factors for healing of COVID-19 infection [ Time Frame: Day 0 ]Hematological pathology Description
- Medical care of Coronavirus infection [ Time Frame: within 12 months after diagnosis ]Describe the management carried out concerning Coronavirus infection and its impact on the treatment of hemopathy.
- national epidemiological monitoring [ Time Frame: through study completion, an average of 2 years ]Allow national epidemiological monitoring and regularly inform the hematology community.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04391946
|Contact: Raoul HERBRECHT, Pr||3 88 68 76 73 73 ext firstname.lastname@example.org|
|Contact: Valérie ROUILLE||4 67 33 26 45 ext +email@example.com|
|Principal Investigator:||Luc-Matthieu FORNECKER, Pr||French Innovative Leukemia Organisation|